Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502696 | 0.93 | ELANE (0.34) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL13254490 | 0.90 | ELANE (0.34) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL3624949 | 0.84 | CYP3A4 (0.40) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL3500465 | 0.81 | ELANE (0.35) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL3497019 | 0.80 | CTSB (0.32) | ELANEKCNH2CTSBPPP3CB | |
| SCHEMBL13282478 | 0.79 | ELANE (0.33) | ELANEKCNH2CTSBPPP3CB | |
| SCHEMBL16385881 | 0.79 | ELANE (0.35) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL733229 | 0.78 | CYP3A4 (0.39) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL14562902 | 0.78 | CYP3A4 (0.41) | ELANEKCNH2CTSBPPP3CBCYP3A4 | |
| SCHEMBL3502758 | 0.78 | ELANE (0.35) | ELANEKCNH2CTSBPPP3CBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927569-B2 | Macrocyclic compounds as antiviral agents | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2178902-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | ANGELETTI P IST RICHERCHE BIO (IT) | 2012-11-28 | — | — | EP | disclosed |
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | MERCK SHARP & DOHME LLC | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183551-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, RNASE1, RRP1B | ELANE 516/4885KCNH2 3970/4885CTSB 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.